{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:52:41Z","timestamp":1775235161377,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.critrevonc.2021.103324","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T22:10:22Z","timestamp":1618956622000},"page":"103324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review"],"prefix":"10.1016","volume":"162","author":[{"given":"Hal","family":"Hirte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-2451","authenticated-orcid":false,"given":"Raymond","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taymaa","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0711-1021","authenticated-orcid":false,"given":"Josee-Lyne","family":"Ethier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauri","family":"Petz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Speakman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8966-1937","authenticated-orcid":false,"given":"Laurie","family":"Elit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"May (2)","key":"10.1016\/j.critrevonc.2021.103324_bib0005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2008.01.005","volume":"109","author":"Alberts","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103324_bib0010","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-19-0226","article-title":"Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without Bevacizumab: results from GOG-0218","volume":"26","author":"Alvarez Secord","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2021.103324_bib0015","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdi223","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study","volume":"16","author":"Aravantinos","year":"2005","journal-title":"Ann. Oncol."},{"issue":"October (15)","key":"10.1016\/j.critrevonc.2021.103324_bib0020","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.ejca.2008.06.035","article-title":"Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a hellenic cooperative oncology group (HeCOG) study","volume":"44","author":"Aravantinos","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"May (1)","key":"10.1016\/j.critrevonc.2021.103324_bib0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2021.103324_bib0030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG","volume":"24","author":"Banerjee","year":"2013","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103324_bib0035","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1470-2045(20)30218-7","article-title":"Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial","volume":"21","author":"Blagden","year":"2020","journal-title":"Lancet Oncol."},{"issue":"November (16)","key":"10.1016\/j.critrevonc.2021.103324_bib0040","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.ejca.2010.06.124","article-title":"Paclitaxel\/carboplatin versus topotecan\/paclitaxel\/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study","volume":"46","author":"Bolis","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"March (9)","key":"10.1016\/j.critrevonc.2021.103324_bib0045","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"December (3)","key":"10.1016\/j.critrevonc.2021.103324_bib0050","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2021.103324_bib0055","first-page":"1241","article-title":"Randomized study of sequential cisplatin-topotecan\/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life","volume":"24","author":"Brotto","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"December (26)","key":"10.1016\/j.critrevonc.2021.103324_bib0060","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103324_bib0065","series-title":"Canadian Cancer Statistics 2019","author":"Canadian Cancer Statistics Advisory Committee","year":"2019"},{"issue":"February(8)","key":"10.1016\/j.critrevonc.2021.103324_bib0070","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10214","key":"10.1016\/j.critrevonc.2021.103324_bib0075","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.critrevonc.2021.103324_bib0080","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"May (8)","key":"10.1016\/j.critrevonc.2021.103324_bib0085","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0959-8049(03)00152-7","article-title":"Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin","volume":"39","author":"Dittrich","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"September (17)","key":"10.1016\/j.critrevonc.2021.103324_bib0090","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"March(7)","key":"10.1016\/j.critrevonc.2021.103324_bib0095","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"Du Bois","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"September (27)","key":"10.1016\/j.critrevonc.2021.103324_bib0100","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"Du Bois","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"May","key":"10.1016\/j.critrevonc.2021.103324_bib0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103324_bib0110","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","author":"Fagotti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"February(4)","key":"10.1016\/j.critrevonc.2021.103324_bib0115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jnci\/djq530","article-title":"Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer","volume":"103","author":"Fruscio","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"November-December (11-12)","key":"10.1016\/j.critrevonc.2021.103324_bib0120","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie","year":"1979","journal-title":"Cancer Treat. Rep."},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2021.103324_bib0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Gonz\u00e1lez Mart\u00edn","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"February (4)","key":"10.1016\/j.critrevonc.2021.103324_bib0130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2005.02.4067","article-title":"Randomized study of the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group comparing quality of life in patients with ovarian cancer treated with cisplatin\/paclitaxel versus carboplatin\/paclitaxel","volume":"24","author":"Greimel","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"November (2)","key":"10.1016\/j.critrevonc.2021.103324_bib0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ygyno.2013.08.014","article-title":"Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy","volume":"131","author":"Greimel","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103324_bib0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdt527","volume":"25","author":"Harano","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103324_bib0145","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103324_bib0150","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol28020107","article-title":"An ontario health (Cancer care Ontario) clinical practice guideline: consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma","volume":"28","author":"Hirte","year":"2021","journal-title":"Curr. Oncol."},{"issue":"October (20)","key":"10.1016\/j.critrevonc.2021.103324_bib0155","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/jnci\/djq362","article-title":"Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel","volume":"102","author":"Hoskins","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2021.103324_bib0160","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","article-title":"Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies","volume":"16","author":"Kang","year":"2009","journal-title":"Ann. Surg. Oncol."},{"issue":"9698","key":"10.1016\/j.critrevonc.2021.103324_bib0165","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"issue":"September (10)","key":"10.1016\/j.critrevonc.2021.103324_bib0170","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"issue":"July (9990)","key":"10.1016\/j.critrevonc.2021.103324_bib0175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2021.103324_bib0180","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103324_bib0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2020.06.025","article-title":"Avelumab in combination with and\/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 javelin ovarian 100 trial","volume":"159","author":"Ledermann","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"April (6)","key":"10.1016\/j.critrevonc.2021.103324_bib0190","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2021.103324_bib0195","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2007.14.9807","article-title":"Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer","volume":"26","author":"Lhomme","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2021.103324_bib0200","first-page":"3646","article-title":"Paclitaxel plus nedaplatin vs. Paclitaxel plus carboplatin in women with epithelial ovarian cancer: a multi-center, randomized, open-label, phase III trial","volume":"15","author":"Li","year":"2018","journal-title":"Oncol. Lett."},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2021.103324_bib0205","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1093\/annonc\/mds060","article-title":"First-line treatment of advanced ovarian cancer with paclitaxel\/carboplatin with or without epirubicin (TEC versus TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG","volume":"23","author":"Lindemann","year":"2012","journal-title":"Ann. Oncol."},{"issue":"September(27)","key":"10.1016\/j.critrevonc.2021.103324_bib0210","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1200\/JCO.2006.09.7527","article-title":"Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar\/AIO and EBMT","volume":"25","author":"Mobus","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103324_bib0215","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2021.103324_bib0220","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103324_bib0225","doi-asserted-by":"crossref","first-page":"S1161","DOI":"10.1016\/j.annonc.2020.08.2261","article-title":"LBA31 Primary results from IMagyn050\/GOG 3015\/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +\/- atezolizumab (atezo) for newly diagnosed stage III\/IV ovarian cancer (OC)","volume":"31","author":"Moore","year":"2020","journal-title":"Ann. Oncol."},{"issue":"January\/February (1 B)","key":"10.1016\/j.critrevonc.2021.103324_bib0230","first-page":"681","article-title":"A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer","volume":"27","author":"Mouratidou","year":"2007","journal-title":"Anticancer Res."},{"issue":"September","key":"10.1016\/j.critrevonc.2021.103324_bib0235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"Onda","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103324_bib0240","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial","volume":"130","author":"Onda","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103324_bib0245","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"issue":"September (17)","key":"10.1016\/j.critrevonc.2021.103324_bib0250","first-page":"3194","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"26","key":"10.1016\/j.critrevonc.2021.103324_bib0255","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"September (27)","key":"10.1016\/j.critrevonc.2021.103324_bib0260","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2021.103324_bib0265","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"issue":"November (9)","key":"10.1016\/j.critrevonc.2021.103324_bib0270","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.bjc.6604026","article-title":"Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group","volume":"97","author":"Ray-Coquard","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103324_bib0275","unstructured":"Sch\u00fcnemann H., Brozek J., Guyatt G., Oxman, A.D. (editors). Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. [updated October 2013]."},{"issue":"October (28)","key":"10.1016\/j.critrevonc.2021.103324_bib0280","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1200\/JCO.2006.10.3846","article-title":"Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Spriggs","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103324_bib0285","series-title":"Stata Statistical Software: Release 15.1","author":"StataCorp","year":"2017"},{"issue":"September (26)","key":"10.1016\/j.critrevonc.2021.103324_bib0290","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103324_bib0295","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"November (22)","key":"10.1016\/j.critrevonc.2021.103324_bib0300","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"17","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"September (10)","key":"10.1016\/j.critrevonc.2021.103324_bib0305","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2021.103324_bib0310","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol."},{"issue":"June (16)","key":"10.1016\/j.critrevonc.2021.103324_bib0315","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"February (4)","key":"10.1016\/j.critrevonc.2021.103324_bib0320","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2006.07.3494","article-title":"Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study","volume":"25","author":"Wenzel","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.critrevonc.2021.103324_bib0325","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian Cancer: society of gynecologic oncology and american society of clinical oncology clinical practice guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:38:52Z","timestamp":1760902732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":65,"alternative-id":["S1040842821001128"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103324","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103324"}}